ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.91
-2.51 (-24.09%)
At close: 4:00PM EDT

7.86 -0.05 (-0.63%)
After hours: 4:39PM EDT

Stock chart is not supported by your current browser
Previous Close10.42
Open7.95
Bid7.77 x 1000
Ask7.95 x 1000
Day's Range7.43 - 8.13
52 Week Range5.42 - 19.15
Volume4,000,881
Avg. Volume267,168
Market Cap107.271M
Beta4.88
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Main Line synthetic cannabinoid developer seeking $32.5M from stock sale
    American City Business Journals4 hours ago

    Main Line synthetic cannabinoid developer seeking $32.5M from stock sale

    The proceeds will be used to advance then company's experimental treatment for Fragile X Syndrome.

  • Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks
    MarketWatch5 hours ago

    Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks

    Valuations today are very high and sentiment is very positive — a bad combination, says Nigam Arora.

  • Benzinga9 hours ago

    Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 19) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Champions Oncology ...

  • MarketWatch12 days ago

    Zynerba stock rebounds after selloff driven by failed cannabis-based skin patch trial

    Shares of Zynerba Pharmaceuticals Inc. rose 7% in Friday trade, recouping some of their prior-session losses that came after the company said an early-stage trial of a cannabinoid skin patch failed to meet its main goals. Zynerba(ZYNE) , which is developing cannabis-based therapies for rare neurospsychiatric disorders, said the trial of ZYN001, which delivers tetrahydrocannabinol (THC) through a transdermal patch, did not achieve its goal of target blood levels of 5 to 14 ng/ml THC in healthy volunteers. THC is the psychoactive ingredient in cannabis and the company was trying to find a way to deliver it without patients having to take it orally, which can make them high.

  • Benzinga15 days ago

    HC Wainwright Unfazed By Zynerba Ending ZYN001: Drug 'Wasn't In Our Numbers'

    Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) stock plummeted 17.8 percent at Thursday’s open after the company ended a Phase 1 study for ZYN001, a tetrahydrocannabinol patch. While there were no adverse ...

  • Benzinga15 days ago

    Zynerba Redirects Resources After ZYN001 Study Fails To Meet Top-Line Results

    Although the pro-drug of tetrahydrocannabinol was “very well tolerated” by the skin and no adverse events were reported, Zynerba is terminating the study. It will instead focus its time and resources on ZYN002 for Fragile X syndrome, developmental and epileptic encephalopathy and adult refractory epilepsy. ZYN002 will begin a pivotal study of ZYN002 in Fragile X in “mid-year 2018” and continue Phase 2 trials for the other two indications.

  • MarketWatch15 days ago

    Zynerba shares slide 17% after trial of cannabis-based skin patch fails to meet goals

    Shares of Zynerba Pharmaceuticals Inc. (zyne) slid about 17% in premarket trade Thursday, after the company said an early-stage trial of a cannabinoid skin patch failed to meet its main goals. The company, which is developing cannabis-based therapies for rare neruospsychiatric disorders, said the trial of ZYN001, a patent-protected, pro-drug of tetrahydrocannabinol (THC) delivered via a transdermal patch, in healthy volunteers, did not achieve its goal of target blood levels of 5 to 14 ng/ml THC. "This Phase 1 study was a single and multiple dose, placebo-controlled first-in-man study to assess the safety and pharmacokinetics of ZYN001 administered as a transdermal patch to healthy adult subjects," Zynerba said in a statement.

  • TheStreet.com24 days ago

    FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

    approaching the U.S launch of its long-awaited Epidiolex epilepsy medicine, the space for cannabis-based drugs to treat the disorder and other maladies is finally moving into reality. London-based GW Pharma said Monday (June 25) the U.S. Food and Drug Administration (FDA) has approved Epidiolex, a cannabinoid-based oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome -- both rare forms of epilepsy -- in patients at least two years old.

  • Benzinga25 days ago

    GW Pharma's Epidiolex Becomes First Cannabis-Based FDA-Approved Drug

    The drug is derived from the cannabidiol of cannabis, and, as the plant is yet to be decriminalized by federal regulators, its approval gives GW Pharma a lead among cannabis-exposed companies in the U.S. financial markets. The FDA seal is nonetheless seen to be a boon for the broader industry. “It makes it harder for Congress to continue to list cannabis as a Schedule I controlled substance,” Debra Borchardt, CEO at cannabis-focused financial media outlet Green Market Report, told Benzinga in April.

  • The Tech Revolutionizing The Billion Dollar Marijuana Business
    Oilprice.com2 months ago

    The Tech Revolutionizing The Billion Dollar Marijuana Business

    Reefer madness is reaching a full-blown frenzy, with total legal worldwide marijuana sales expected to surpass $63 billion in less than ten years. And now the tech behind bitcoin is poised to take the cannabis boom to the next level

  • Investopedia2 months ago

    Pot Stock Winners of the Week

    Here are the week's four biggest marijuana stock winners.

  • Interested In Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)? Here’s How It Performed Recently
    Simply Wall St.2 months ago

    Interested In Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)? Here’s How It Performed Recently

    Understanding how Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense checkRead More...

  • Associated Press2 months ago

    Zynerba: 1Q Earnings Snapshot

    The Devon, Pennsylvania-based company said it had a loss of 91 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • What Do Analysts Think About Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) Earnings Trend?
    Simply Wall St.3 months ago

    What Do Analysts Think About Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) Earnings Trend?

    The most recent earnings announcement Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) released in December 2017 confirmed that losses became smaller relative to the prrior year’s level as a result of recent tailwindsRead More...

  • Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes
    Investor's Business Daily3 months ago

    Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes

    GW Pharmaceuticals, Insys Therapeutics and Zynerba Pharmaceuticals are using cannabis-based therapies to treat a myriad of disorders, including seizures.

  • Should You Buy Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) At $7.98?
    Simply Wall St.4 months ago

    Should You Buy Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) At $7.98?

    Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...

  • Analysts Expect Breakeven For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)
    Simply Wall St.4 months ago

    Analysts Expect Breakeven For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

    Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE): Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The US$136.43M market-cap company announced a latest loss of -US$32.01M on 31 December 2017 forRead More...

  • Associated Press4 months ago

    Zynerba reports 4Q loss

    The Devon, Pennsylvania-based company said it had a loss of 60 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • American City Business Journals5 months ago

    Main Line pharma company plans key study of Fragile X syndrome therapy

    Zynerba Pharmaceuticals said Monday it plans — with the Food and Drug Administration's approval — to initiate a single pivotal study later this year to support a new drug application for its experimental cannabis-based treatment for Fragile X Syndrome. Fragile X is a rare genetic developmental disability that is a leading known cause of both inherited intellectual disability and autism spectrum disorder. Zynerba, of Devon, Pa, said its game plan for its new drug candidate, ZYN002, came following a meeting with the Food and Drug Administration.

  • 24/7 Wall St.6 months ago

    Can Zynerba Pharma Shares Really Still Double in These High Times?

    While Zynerba's share price is still roughly half of last year's peak, the company has gotten attention from Wall Street with big upside in analyst calls in recent days.

  • Can This Beaten-Down Marijuana Stock Roar Back in 2018?
    Motley Fool7 months ago

    Can This Beaten-Down Marijuana Stock Roar Back in 2018?

    Zynerba faces some big questions heading into the new year.

  • Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE): Does -3.8% EPS Drop In A Year Reflect The Long-Term Trend?
    Simply Wall St.7 months ago

    Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE): Does -3.8% EPS Drop In A Year Reflect The Long-Term Trend?

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) track record on a high level, toRead More...

  • Benzinga7 months ago

    Zynerba Pharmaceuticals Volatile After Epilepsy Study Results

    Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded ...

  • Is It The Right Time To Buy Zynerba Pharmaceuticals Inc (ZYNE)?
    Simply Wall St.8 months ago

    Is It The Right Time To Buy Zynerba Pharmaceuticals Inc (ZYNE)?

    Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGM in the over the last fewRead More...